Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia.
Prev Med. 2011 Oct;53 Suppl 1:S29-35. doi: 10.1016/j.ypmed.2011.08.015.
Australia commenced an ongoing school based government funded human papillomaviruses (HPV) (cervical cancer prevention) vaccination program in April 2007 for adolescent females aged 12-13 years. In addition, up to December 31, 2009, a catch-up program for young females 13-26 years of age was offered: a school-based vaccination program was used to offer HPV vaccine to girls enrolled in school (14-17 years), and general practitioners or other community health provider offered vaccine to young women aged 18-26 years. To date, only the quadrivalent vaccine (HPV 6/11/16/18) has been utilized in the funded program. Acceptance of the vaccine is high with coverage of 3 doses of the HPV vaccine in the school age cohort around 70%, and just over 30% in the older age cohort. Since the vaccination program was initiated, a reduction in new cases of genital warts of 73% among vaccine eligible age females has been evidenced in STI clinics across Australia. A reduction of 44% of new cases in young males (not a part of the free program) was also documented during this same time period, suggesting significant herd immunity. Similarly, in the state of Victoria, a small but significant decrease in high grade abnormalities in Pap screening findings has been reported in young women<18 years for the period 2007-9, as compared to pre-vaccination. Challenges for the future include how we can sustain and improve HPV vaccination coverage in young Australian women, while maintaining cervical cancer screening participation and reviewing cervical cancer screening methods.
澳大利亚于 2007 年 4 月开始为 12-13 岁的青春期少女提供基于学校的政府资助的人乳头瘤病毒（HPV）（宫颈癌预防）疫苗接种计划。此外，截至 2009 年 12 月 31 日，为 13-26 岁的年轻女性提供了一项补种计划：学校为在校女孩（14-17 岁）提供 HPV 疫苗接种计划，普通医生或其他社区卫生提供者为 18-26 岁的年轻女性提供疫苗。迄今为止，资助计划中仅使用了四价疫苗（HPV 6/11/16/18）。疫苗的接种率很高，在学龄人群中，HPV 疫苗的 3 剂覆盖率约为 70%，而年龄较大人群的覆盖率略高于 30%。自疫苗接种计划启动以来，澳大利亚各地的性传播感染诊所已经证明，在疫苗接种年龄女性中，生殖器疣的新发病例减少了 73%。在此期间，同样也记录到年轻男性（不属于免费计划）的新发病例减少了 44%，这表明存在显著的群体免疫。同样，在维多利亚州，与接种疫苗前相比，2007-2009 年期间，18 岁以下年轻女性的巴氏涂片筛查结果中高级别异常的情况也出现了微小但显著的下降。未来的挑战包括如何在保持宫颈癌筛查参与度和审查宫颈癌筛查方法的同时，提高澳大利亚年轻女性的 HPV 疫苗接种率。
